Results 141 to 150 of about 2,363,919 (190)

Advances in Functional Genomics and Biotechnology for Enhancing Therapeutic Potential of Medicinal Plants. [PDF]

Int J Mol Sci
Zaman W, Park S.
europepmc   +1 more source

Microtubules in Spinal Cord Injury: From Cytoskeletal Dysregulation to Therapeutic Regeneration. [PDF]

J Neurochem
Fischer I, Baas PW.
europepmc   +1 more source

Special Issue "New Drugs Regulating Cytoskeletons in Human Health and Diseases". [PDF]

Int J Mol Sci
Breuzard G, Robin M, Kovacic H.
europepmc   +1 more source

Hybrid Microtubule-Solid-State Nanopores for Single-Molecule Analysis. [PDF]

Electrophoresis
O'Donohue M, Gu C, Kim B, Lee KK, Lee S, Ahn CW, Choi MC, Kim MJ.   +7 more
europepmc   +1 more source

Design and Pictet-Spengler enabled synthesis of carboxamide-substituted imidazo[1,2-<i>a</i>]quinoxalines as dual EGFR and tubulin targeting anticancer agents. [PDF]

J Enzyme Inhib Med Chem
Chatterjee J, Joshi G, Jha V, Bhujbal SM, Rathour S, Majumdar S, Wahajuddin M, Bharatam PV, Kumar R.   +8 more
europepmc   +1 more source

Mechanisms of Taxol Resistance Related to Microtubules [PDF]

Oncogene, 2003
Since its approval by the FDA in 1992 for the treatment of ovarian cancer, the use of Taxol has dramatically increased. Although treatment with Taxol has led to improvement in the duration and quality of life for some cancer patients, the majority eventually develop progressive disease after initially responding to Taxol treatment.
Hayley M McDaid, Pascal Verdier-Pinard, Susan Band Horwitz   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Taxol Resistance

Chemotherapy, 2000
<i>Background:</i> Taxol has gained considerable attention in cancer therapy in recent years and is successfully used in treating a variety of tumors, including those of the breast, ovary and lung. Despite its preclinical and clinical success, the ability of tumors to develop an acquired resistance to drugs used for treatment remains a ...
A Fellous, Arlette Fellous
exaly   +3 more sources

Intracellular Self-Assembly of Taxol Nanoparticles for Overcoming Multidrug Resistance

Angewandte Chemie - International Edition, 2015
AbstractMultidrug resistance (MDR) remains the biggest challenge in treating cancers. Herein we propose the intracellular self‐assembly of nanodrugs as a new strategy for overcoming MDR. By employing a biocompatible condensation reaction, we rationally designed a taxol derivative Ac‐Arg‐Val‐Arg‐Arg‐Cys(StBu)‐Lys(taxol)‐2‐cyanobenzothiazole (CBT‐Taxol ...
Huafeng Zhang, Linna An, Yue Yuan
exaly   +3 more sources

Paclitaxel (Taxol®) Mechanisms of Resistance

1996
Paclitaxel (Taxol #®) is one of the most promising new anticancer agents developed in recent years [1]. Taxol® has been approved for the treatment of refractory ovarian [2,3] and breast cancer [4] in several countries, and has shown activity against after human malignancies, such as lung cancer head and neck cancer, esophageal cancer, hematological ...
A M, Casazza, C R, Fairchild
openaire   +2 more sources

Taxol Is Active in Platinum-Resistant Endometrial Adenocarcinoma

American Journal of Clinical Oncology, 1996
Taxol, 170 mg/m2 by 3-h infusion every 3 weeks, was administered to seven patients with primarily advanced or recurrent endometrial cancer with progressive disease on platinum analogues. By standard response criteria, there were three clinical responders (43%; 95% confidence limits, 6-80%) and one disease stabilization.
H L, Woo, K D, Swenerton, P J, Hoskins
openaire   +2 more sources